Metformin treatment for Type 2 diabetes in pregnancy?

被引:23
作者
Simmons, David [1 ,2 ]
机构
[1] Addenbrookes Hosp, Wolfson Diabet & Endocrinol Clin, Inst Metab Sci, Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 2QQ, England
[2] Univ Melbourne, Dept Rural Hlth, Shepparton, Vic, Australia
关键词
Type; 2; diabetes; Pregnancy; Metformin; Glucose; Malformation; Insulin; Macrosomia; Pre-eclampsia; POLYCYSTIC-OVARY-SYNDROME; ORAL HYPOGLYCEMIC AGENTS; RELEASE METFORMIN; HUMAN-MILK; WOMEN; INSULIN; MELLITUS; THERAPY; RISK; MANAGEMENT;
D O I
10.1016/j.beem.2010.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metformin lowers blood glucose by reducing hepatic glucose output, increasing insulin sensitivity and enhancing peripheral glucose uptake. Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant. Studies to date in Type 2 diabetes in pregnancy, gestational diabetes and polycystic ovarian syndrome are reassuring. Metformin is not considered teratogenic. There is sufficient evidence that metformin is safe used throughout pregnancy, with no worsening of obstetric or perinatal outcomes. Women may benefit from the lesser weight gain. The long-term risks to the offspring remain inadequately researched, with no evidence of harm up to 2 years, and no suggestions of later complications in countries using metformin for many years. Metformin is recommended for use in pregnancies complicated by Type 2 diabetes, but women should be informed of the evidence regarding its associated risks and benefits to enable an informed choice over its use. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:625 / 634
页数:10
相关论文
共 48 条
[1]  
[Anonymous], MAN WOM OB PREGN
[2]   Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study [J].
Balani, J. ;
Hyer, S. L. ;
Rodin, D. A. ;
Shehata, H. .
DIABETIC MEDICINE, 2009, 26 (08) :798-802
[3]   Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].
Bowker, SL ;
Majumdar, SR ;
Veugelers, P ;
Johnson, JA .
DIABETES CARE, 2006, 29 (02) :254-258
[4]   Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome [J].
Carlsen, Sven M. ;
Kjotrod, Sigrun ;
Vanky, Eszter ;
Romundstad, Pal .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2007, 86 (02) :145-150
[5]   METFORMIN IN MANAGEMENT OF PREGNANT INSULIN-INDEPENDENT DIABETICS [J].
COETZEE, EJ ;
JACKSON, WPU .
DIABETOLOGIA, 1979, 16 (04) :241-245
[6]  
Coetzee EJ., 1986, Diabetes Res Clin Pract, V1, P281
[7]   The influence of glucose-lowering therapies on cancer risk in type 2 diabetes [J].
Currie, C. J. ;
Poole, C. D. ;
Gale, E. A. M. .
DIABETOLOGIA, 2009, 52 (09) :1766-1777
[8]   EFFECTS OF THE BIGUANIDE CLASS OF ORAL HYPOGLYCEMIC AGENTS ON MOUSE EMBRYOGENESIS [J].
DENNO, KM ;
SADLER, TW .
TERATOLOGY, 1994, 49 (04) :260-266
[9]   POSTPRANDIAL VERSUS PREPRANDIAL BLOOD-GLUCOSE MONITORING IN WOMAN WITH GESTATIONAL DIABETES-MELLITUS REQUIRING INSULIN THERAPY [J].
DEVECIANA, M ;
MAJOR, CA ;
MORGAN, MA ;
ASRAT, T ;
TOOHEY, JS ;
LIEN, JM ;
EVANS, AT .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (19) :1237-1241
[10]   Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal [J].
Dunaif, Andrea .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (05) :272-283